Multiple myeloma is commonly associated with a reduction of non-paraprotein immunoglobulins, resulting in a higher risk of infections that represent the leading cause of the patients' death. Therefore, immunoglobulin replacement therapy appears a logical approach.

A total number of 46 myeloma patients were randomly enrolled: 24 of them were assigned to receive subcutaneous immunoglobulins, and 22 were controls. The primary endpoint was the evaluation of the annual rate of severe infections in immunoglobulins-receiving patients as compared with those untreated. Subcutaneous immunoglobulins-treated patients showed a significantly lower number of severe infections per year. Adverse events were limited to the site of infusion and were easily manageable. Health-related quality of life was significantly better in subcutaneous immunoglobulins-receiving patients.

By decreasing the rate of infections, the prophylactic administration of SCIg improves both adherence to chemotherapy and health-related quality of life, and is cost-effective by reducing the need of hospitalization and the use of antibiotics.

多发性骨髓瘤通常与非副蛋白免疫球蛋白减少有关，导致感染风险升高，这代表了患者死亡的主要原因。因此，免疫球蛋白替代疗法似乎是一种合理的方法。

总共随机入选了46名骨髓瘤患者：其中24名被分配接受皮下免疫球蛋白治疗，而22名是对照组。主要终点是接受免疫球蛋白的患者与未接受治疗的患者相比，每年严重感染率的评估。皮下免疫球蛋白治疗的患者每年出现的严重感染数量显着降低。不良事件仅限于输注部位，易于管理。接受皮下免疫球蛋白的患者的健康相关生活质量显着提高。

通过降低感染率，预防性给予SCIg既可以提高对化学疗法的依从性，又可以改善与健康相关的生活质量，并且通过减少住院和使用抗生素的方式具有成本效益。